University of South Florida, 12901 Bruce B. Downs Blvd., MDC 27, Tampa, FL 33612, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1664-72. doi: 10.1158/1055-9965.EPI-12-0448.
This study examines efficacy of a lay patient navigation (PN) program aimed to reduce time between a cancer abnormality and definitive diagnosis among racially/ethnically diverse and medically underserved populations of Tampa Bay, Florida.
Using a cluster randomized design, the study consisted of 11 clinics (six navigated; five control). Patients were navigated from time of a breast or colorectal abnormality to diagnostic resolution, and to completion of cancer treatment. Using a generalized mixed-effects model to assess intervention effects, we examined: (i) length of time between abnormality and definitive diagnosis, and (ii) receipt of definitive diagnosis within the 6-month minimum follow-up period.
A total of 1,267 patients participated (588 navigated; 679 control). We also included data from an additional 309 chart abstractions (139 navigated arm; 170 control arm) that assessed outcomes at baseline. PN did not have a significant effect on time to diagnostic resolution in multivariable analysis that adjusted for race-ethnicity, language, insurance status, marital status, and cancer site (P = 0.16). Although more navigated patients achieved diagnostic resolution by 180 days, results were not statistically significant (74.5% navigated vs. 68.5% control, P = 0.07).
PN did not impact the overall time to completion of diagnostic care or the number of patients who reached diagnostic resolution of a cancer abnormality. Further evaluation of PN programs applied to other patient populations across the cancer continuum is necessary to gain a better perspective on its effectiveness.
PN programs may not impact timely resolution of an abnormality suspicious of breast or colorectal cancer.
本研究考察了一个针对佛罗里达州坦帕湾的不同种族/民族和医疗服务不足人群的非专业患者导航(PN)项目在减少癌症异常与明确诊断之间时间的疗效。
采用集群随机设计,该研究包括 11 个诊所(6 个接受导航;5 个对照)。患者从乳房或结直肠异常到诊断明确,再到癌症治疗完成,都接受了导航。使用广义混合效应模型评估干预效果,我们检查了:(i)异常与明确诊断之间的时间长度,以及(ii)在 6 个月的最低随访期内获得明确诊断的情况。
共有 1267 名患者参与(588 名接受导航;679 名对照)。我们还纳入了另外 309 份图表摘要的数据(139 名接受导航组;170 名对照组),以评估基线时的结果。在调整了种族/民族、语言、保险状况、婚姻状况和癌症部位等因素的多变量分析中,PN 对诊断分辨率的时间没有显著影响(P=0.16)。尽管接受导航的患者在 180 天内达到诊断分辨率的比例更高,但结果并不显著(74.5%的接受导航组与 68.5%的对照组相比,P=0.07)。
PN 没有影响完成诊断护理的总体时间,也没有影响达到癌症异常诊断分辨率的患者数量。需要进一步评估 PN 计划在癌症连续体中的其他患者群体中的应用,以更好地了解其效果。
PN 计划可能不会影响对疑似乳腺癌或结直肠癌的异常的及时解决。